Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Ahead of Print

Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma: JFMC 29–0003

1 Department of Surgery, Kushiro Rosai Hospital, Kushiro, Japan
2 Department of Surgery, Southern TOHOKU General Hospital, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan
3 Department of Surgery, Keio University School of Medicine, Tokyo, Japan
4 Department of Surgery, Machida Keisen Hospital, Tokyo, Japan
5 Department of Medical Laboratory and Blood Center, Asahikawa Medical University, Asahikawa, Japan
6 Department of Surgery, Hijirigaoka Hospital, Date, Japan
7 Department of Gastrointestinal Surgery, Toho University, Tokyo, Japan
8 Department of Surgery, Totsuka Kyouritsu Daiichi Hospital, Yokohama, Japan
9 Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan
10 Department of Surgery, Tokai Central Hospital, Kakamigahara, Japan
11 Translational Research and Clinical Trial Center, Hokkaido University Hospital, Sapporo, Japan
12 ese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan

Correspondence Address:
Michitaka Honda,
Department of Surgery, Southern TOHOKU General Hospital, Southern TOHOKU Research Institute for Neuroscience, Koriyama, 7-115 Yatsuyamada, Koriyama, Fukushima 963-8563
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Background: The feasibility and efficacy of adjuvant hepatic arterial infusion (HAI) in preventing the development of liver metastases in patients with advanced colon carcinoma have not been validated. The aim of this randomized controlled study was to compare the feasibility of HAI and the protective effect against liver metastasis after curative resection to those of systemic chemotherapy. Methods: Between July 2000 and June 2003, 91 patients were enrolled. Patients were randomly assigned to receive 5-fluorouracil (5-FU) via continuous venous infusion (CVI) or intra-hepatic arterial weekly high-dose 5-FU (WHF). The primary endpoint was overall survival (OS). Results: In the WHF group, the cumulative failure rate of hepatic arterial catheterization was 16.7% at 6 months. The occurrence of grade 3 adverse events was comparable between the groups. The 5-year OS rates were 59.0% in the CVI group and 34.9% in the WHF group (P =0.164). CVI tended to show a protective effect against liver metastasis regarding the 5-year liver-specific cumulative recurrence rate: CVI, 45.0% vs. WHF, 68.3%; P =0.037). Conclusion: HAI therapy has a certain protective effect against liver metastasis after curative resection in patients with colorectal cancer. However, this therapy did not contribute to any marked improvement in their overall survival.

Print this article
  Search Pubmed for
    -  Kusano M
    -  Honda M
    -  Okabayashi K
    -  Akimaru K
    -  Kino S
    -  Tsuji Y
    -  Watanabe M
    -  Suzuki S
    -  Yoshikawa T
    -  Sakamoto J
    -  Oba K
    -  Saji S
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded14    

Recommend this journal